GOA Therapeutics Corp
About GOA Therapeutics Corp
GOA Therapeutics Corporation is a research-stage, preclinical biotechnology company dedicated to developing innovative therapies to address significant unmet medical needs in acute-care medicine. Its lead program, GOA26, is a first-in-class drug candidate in preclinical development for acute alcohol intoxication and poisoning, designed to rapidly lower blood alcohol concentrations and sequester acetaldehyde. The company presented IND-enabling preclinical data and brings together expertise in drug development, emergency medicine, trauma care, medical affairs and commercialization.
- 🔗 GOA Therapeutics Emerges from Stealth with $15.5 Million in
- 🔗 GOA Therapeutics Files with SEC for Proposed Public Offering, Contemplates Issuing Up to $300 Million in Stock
- 🔗 part ii - offering circular
- 🔗 GOA Therapeutics Unveils New Data for GOA26, a First-in-Class Drug Candidate for Acute Alcohol Intoxication and Poisoning | Markets Insider
- 🔗 Goa University - 2026 Company Profile, Funding & Competitors - Tracxn
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- GOA Therapeutics emerged from stealth with $15.5 million and unveiled GOA26 for acute alcohol intoxication.
- Company filed Reg A for $67.5 million and contemplates up to $300 million public offering.
- Lead candidate GOA26 is in preclinical development with new data on biochemical stabilization.
- Focuses on first-in-class therapies for unmet needs in acute-care medicine.
- Headquartered in West Palm Beach, FL with website goathera.com.
Ask StreetZero about GOA Therapeutics Corp
Put our AI to work on this deal.
Similar companies
Other Other deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account